Adding Talazoparib to Enzalutamide Boosts PFS in Metastatic Prostate Cancer
SAN FRANCISCO — Treatment with the PARP inhibitor talazoparib (Talzenna) plus enzalutamide (Xtandi) significantly improved radiographic progression-free survival (rPFS) compared with enzalutamide plus placebo in patients with metastatic castration-resistant prostate cancer (mCRPC), the phase III TALAPRO-2 trial showed. Among 805 randomized patients, rPFS assessed by blinded independent central review was not reached in those who […]